中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

865 records (took 0.036 seconds)

    EXPRESSION SYSTEM FOR PRODUCING PROTEIN HAVING A N-TERMINAL PYROGLUTAMATE RESIDUE
    121.
    发明申请
    EXPRESSION SYSTEM FOR PRODUCING PROTEIN HAVING A N-TERMINAL PYROGLUTAMATE RESIDUE 有权
    用于生产具有N-末端吡咯烷酸残基的蛋白质的表达系统

    公开(公告)号：US20160273015A1

    公开(公告)日：2016-09-22

    申请号：US14661052

    申请日：2015-03-18

    Applicant: Academia Sinica

    Inventor： Andrew H. -J. Wang ,  Kai-Fa Huang ,  Yan-Ping Shih

    IPC: C12P21/00 ,  C07K14/52 ,  C12N15/70

    CPC classification number: C12N15/70 ,  C07K14/52 ,  C07K2319/21 ,  C07K2319/24 ,  C07K2319/50 ,  C12N9/104 ,  C12P21/02 ,  C12Y203/02005

    Abstract: Disclosed herein is an expression system and uses thereof. The expression system comprises two vectors that express two fusion proteins and a glutaminyl cyclase (QC) with E45Q mutation, so as to autonomously produce a target protein having a N-terminal pyroglutamate (pGlu) residue in a host cell. The first fusion protein is composed of a maltose binding protein (MBP) and a tobacco etch virus protease (TEVP); and the second fusion protein includes in sequence, a thioredoxin, a S-tag, a linker having a TEVP recognition site therein, a target protein, and a (His)-6-tag. The second fusion protein is cleaved by the TEVP that is expressed by the first fusion protein, and then catalyzed by QC with E45Q mutation so as to autonomously produce the target protein having a N-terminal pGlu residue in the host cell.

    Abstract translation: 本文公开了表达系统及其用途。 表达系统包含两个表达两种融合蛋白的载体和具有E45Q突变的谷氨酰胺环化酶（QC），以便在宿主细胞中自主产生具有N-末端焦谷氨酸（pGlu）残基的靶蛋白。 第一个融合蛋白由麦芽糖结合蛋白（MBP）和烟草蚀刻病毒蛋白酶（TEVP）组成; 并且第二融合蛋白依次包含硫氧还蛋白，S-标签，其中具有TEVP识别位点的接头，靶蛋白质和（His）-6标签）。 第二融合蛋白被由第一融合蛋白表达的TEVP切割，然后通过QC进行E45Q突变催化，从而自主产生在宿主细胞中具有N末端pGlu残基的靶蛋白。

    TILAPIA (OREOCHROMIS NILOTICUS) MYOSIN LIGHT CHAIN 3 PROMOTER
    125.
    发明申请
    TILAPIA (OREOCHROMIS NILOTICUS) MYOSIN LIGHT CHAIN 3 PROMOTER 有权
    TILAPIA（OREOCHROMIS NILOTICUS）MYOSIN LIGHT CHAIN 3 PROMOTER

    公开(公告)号：US20160113252A1

    公开(公告)日：2016-04-28

    申请号：US14920497

    申请日：2015-10-22

    Applicant: Yu-Ho Lin ,  ACADEMIA SINICA

    Inventor： Yu-Ho LIN ,  Jyh-Yih CHEN

    IPC: A01K67/027 ,  C07K14/46 ,  C12N15/85

    CPC classification number: A01K67/0275 ,  A01K2217/052 ,  A01K2217/206 ,  A01K2227/40 ,  A01K2267/02 ,  A01K2267/0393 ,  C07K14/461 ,  C12N15/8509 ,  C12N2830/008

    Abstract: The preset invention relates to a promoter to target a fluorescent protein to the muscles of fish, such as A. nigrofasciatus, for ornamental purposes, which is a Mlc3 (myosin, light polypeptide 3, skeletal muscle) promoter. The Mlc3 promoter has the nucleotides of tilapia (Oreochromis niloticus) myosin light chain 3 (Mlc3) promoter region, which is potential to be a tilapia Mlc3 promoter to enhance protein expression in muscle of fish, particularly for the generation of ornamental fish.

    Abstract translation: 本发明涉及将荧光蛋白靶向鱼（例如黑曲霉）的肌肉用于观赏目的的启动子，其为Mlc3（肌球蛋白，轻链多肽3，骨骼肌）启动子。 Mlc3启动子具有罗非鱼（Oreochromis niloticus）肌球蛋白轻链3（Mlc3）启动子区的核苷酸，其可能是罗非鱼Mlc3启动子，以增强鱼肌肉中的蛋白质表达，特别是用于产生观赏鱼。

    SUPPRESSION OF CANCER METASTASIS
    128.
    发明申请
    SUPPRESSION OF CANCER METASTASIS 有权
    抑制癌症分期

    公开(公告)号：US20160051634A1

    公开(公告)日：2016-02-25

    申请号：US14836380

    申请日：2015-08-26

    Applicant: Academia Sinica

    Inventor： Shu-Mei Liang ,  Ching-Feng Chiu ,  Shao-Wen Hung ,  Jei-Ming Peng ,  Chi-Ming Liang

    IPC: A61K38/38 ,  A61N5/10 ,  C12N7/00 ,  A61K38/16 ,  A61K45/06

    CPC classification number: A61K38/385 ,  A61K38/162 ,  A61K38/38 ,  A61K45/06 ,  A61K47/643 ,  A61N5/10 ,  C07K14/765 ,  C12N7/00 ,  C12N2770/32133

    Abstract: Methods of using fibrillar proteins are provided for suppressing cancer metastasis. Cancer metastasis is the most common cause of treatment failure and death in cancer patients. Tumor cell invasion and/or migration can be significantly inhibited after fibrillar proteins (rVP1, F-HSA, and F-BSA) treatment in vitro. In addition, rVP1 can significantly suppress murine and human breast cancer metastasis and human prostate and ovarian cancer metastasis in vivo while F-HSA can significantly suppress murine breast cancer metastasis.

    Abstract translation: 提供使用纤维蛋白的方法用于抑制癌症转移。 癌症转移是癌症患者治疗失败和死亡的最常见原因。 在纤维状蛋白（rVP1，F-HSA和F-BSA）体外处理后，可以显着抑制肿瘤细胞侵袭和/或迁移。 另外，rVP1可以显着抑制鼠体内人乳腺癌转移和人前列腺癌和卵巢癌转移，而F-HSA可显着抑制鼠乳腺癌转移。

    ANTIMICROBIAL PEPTIDES DERIVED FROM HEPATITIS B VIRUS CORE PROTEIN ARGININE-RICH DOMAIN
    130.
    发明申请
    ANTIMICROBIAL PEPTIDES DERIVED FROM HEPATITIS B VIRUS CORE PROTEIN ARGININE-RICH DOMAIN 审中-公开
    乙型肝炎病毒核蛋白衍生自丙型肝炎病毒的抗微生物肽

    公开(公告)号：US20160002300A1

    公开(公告)日：2016-01-07

    申请号：US14766359

    申请日：2014-02-05

    Applicant: Chi-Ming LIANG ,  Academia Sinica

    Inventor： Chiaho Shih ,  Heng-Li Chen ,  Pei-Yi Su

    IPC: C07K14/005 ,  C12N7/00

    CPC classification number: C07K14/005 ,  A61K38/00 ,  A61K39/12 ,  A61K39/292 ,  C12N7/00 ,  C12N2730/10133 ,  C12N2730/10134

    Abstract: A pharmaceutical composition for use in killing and/or inhibiting the growth and/or proliferation of a microorganism in a subject in need thereof, or for treating a subject afflicted with a microbial infection is disclosed. The composition comprises: (a) an effective amount of an isolated peptide, wherein the peptide comprises the arginine-rich carboxy-terminal region of hepatitis B virus core protein (HBc) and exhibits an antimicrobial activity; and (b) a pharmaceutically acceptable carrier. The peptide exhibits an activity against Gram-negative bacteria, Gram-positive bacteria, and/or fungi.

    Abstract translation: 公开了用于杀死和/或抑制有需要的受试者中的微生物的生长和/或增殖或用于治疗受到微生物感染的受试者的药物组合物。 所述组合物包含：（a）有效量的分离的肽，其中所述肽包含乙型肝炎病毒核心蛋白（HBc）的富含精氨酸的羧基末端区域并显示出抗微生物活性; 和（b）药学上可接受的载体。 肽表现出对革兰氏阴性菌，革兰氏阳性菌和/或真菌的活性。

Patent Agency Ranking